AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and Processes
Cannabinoid Receptor AgonistsReceptors, CannabinoidCannabinoidsReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2BenzoxazinesCyclohexanolsNaphthalenesCannabinoid Receptor AntagonistsDronabinolCannabinoid Receptor ModulatorsReceptors, DrugMorpholinesEndocannabinoidsPyrazolesPolyunsaturated AlkamidesPiperidinesBornanesArachidonic AcidsAnalgesicsGlyceridesDose-Response Relationship, DrugAmidohydrolasesRats, Sprague-DawleyCannabidiolPainCalcium Channel BlockersDrug InteractionsRats, WistarMonoacylglycerol LipasesSynaptic TransmissionPurinergic P1 Receptor AgonistsPain MeasurementMice, Inbred C57BLSerotonin Receptor AgonistsNeuronsDopamine AgonistsSignal TransductionCannabinolCannabisSerotonin 5-HT1 Receptor AgonistsCells, CulturedDisease Models, AnimalSerotonin 5-HT2 Receptor AgonistsAdenosine A1 Receptor AgonistsLigandsIndolesReceptors, Opioid, muRadioligand AssayGuanosine 5'-O-(3-Thiotriphosphate)GABA AgonistsReceptors, Opioid, kappaAdenosine A2 Receptor AgonistsMice, KnockoutCHO CellsGABA-A Receptor AgonistsBehavior, AnimalGABA-B Receptor AgonistsSerotonin 5-HT4 Receptor AgonistsDrug Inverse AgonismBrainAdrenergic alpha-2 Receptor AgonistsPurinergic P2 Receptor AgonistsCarbamatesHippocampusEthanolaminesCricetinaeEnkephalin, Ala(2)-MePhe(4)-Gly(5)-TRPV Cation ChannelsReceptors, OpioidCyclic AMPBenzodioxolesReceptors, Dopamine D2CapsaicinResorcinolsBinding, CompetitivePertussis ToxinReceptors, G-Protein-CoupledAdenosine A3 Receptor AgonistsExcitatory Amino Acid Agonistsgamma-Aminobutyric AcidMuscarinic AgonistsHallucinogensHistamine AgonistsMice, Inbred ICRMotor ActivityDrug ToleranceAdenosineHyperalgesiaCyclohexanesPatch-Clamp Techniques

Estrogenic regulation of limbic cannabinoid receptor binding. (73/177)

 (+info)

Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain. (74/177)

 (+info)

Pharmacological characterization of GPR55, a putative cannabinoid receptor. (75/177)

 (+info)

Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids. (76/177)

 (+info)

N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. (77/177)

 (+info)

Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs. (78/177)

 (+info)

Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase. (79/177)

 (+info)

Analysis of the effect of neuropeptides and cannabinoids in gastric mucosal defense initiated centrally in the rat. (80/177)

Increasing number of evidence suggest that gastric mucosal protection can be induced also centrally. Several neuropeptides, such as TRH, amylin, adrenomedullin, enkephalin, beta-endorphin, nociceptin, nocistatin, ghrelin or orexin given centrally induce gastroprotection and the dorsal vagal complex and vagal nerve may play prominent role in this centrally initiated effect. Since also cannabinoid receptors are present in the dorsal vagal complex, we aimed to study whether activation of central cannabinoid receptors result in gastric mucosal defense and whether there is an interaction between cannabinoids and endogenous opioids. Gastric mucosal damage was induced by 100% ethanol in rats. The cannabinoids were given intravenously (i.v.) or intracerebroventricularly (i.c.v.), while the antagonists were given i.c.v or intracisternally (i.c.). Gastric lesions were evaluated macroscopically 60 min later. Anandamide, methanandamide and WIN55,212-2 reduced ethanol-induced mucosal lesions after both peripheral (0.28-5.6 micromol/kg, 0.7-5.6 micromol/kg and 0.05-0.2 mumol/kg i.v., respectively) and central (2.9-115 nmol/rat, 0.27-70 nmol/rat and 1.9-38 nmol/rat i.c.v., respectively) administration. The gastroprotective effect of anandamide and methanandamide given i.c.v. or i.v.was reversed by the CB(1) receptor antagonist SR141716A (2.16 nmol i.c.v.). Naloxone (27.5 nmol i.c.v.) also antagonized the effect of i.c.v. or i.v. injected anandamide and WIN55,212-2, but less affected that of methanandamide. The gastroprotective effect of anandamide was diminished also by endomorphin-2 antiserum. In conclusion it was first demonstrated that activation of central CB(1) receptors results in gastroprotective effect. The effect is mediated at least partly by endogenous opioids.  (+info)